PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
OMB control number.

	Substitute for form 1449/PTO			Complete if Known		
	INFORMATION	DISCL	OSURE	Application Number	09/337,675	
	STATEMENT BY APPLICANT			Filing Date	6/22/1999	
	Date Submitted: July 19, 2010			First Named Inventor	Rajeev A. Jain et al.	
Date Submitted, July 19, 2010			15, 2010	Art Unit	1615	
	(use as many sheets as necessary)			Examiner Name	Susan T. Tran	
Sheet	1	of	1	Attorney Docket Number	029318-0497	

U.S. PATENT DOCUMENTS					
Examin er Initials*	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
						-

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), titlem (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-ii-number(s), publisher, city and/or country where published.				
	A1	Decision on Rejection cited in related Japanese Patent Application No. 2001-583733, dated June 9, 2010, 3 pgs.			
	A2	"Design and Evaluation of Oral Administration Drug Formulation", <i>Pharmaceutical Industry Time Signal Company</i> , pp. 167-168 (1995).			
			and the second		

Examiner Signature	Date Considered	

\*EXAMINER: Infinal if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant. In Applicant's unique classified explored in unimple regionary of the MPEP 901.04.3 Enter Office that issued the document. by the two-letter code (WIPPO Standard ST 3), 4 For Japanese patient Documents at www.uspto.gov or MPEP 991.04.3 Enter Office that issued the document. by the objective of the patient document. Skind of document. Skind of document. Skind of document. Skind of colored to the regind of the Emperor must precede the serial number of the patient document. Skind of document is the appropriate symbols as indicated on the document under VIPPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPT 0 to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the confidential state of the confidential state o